Skip to content
OpenCapital
Get started

Crinetics Pharmaceuticals CRNX Business Segments — Research And Development Personnel Expenses

Similar metrics at other companies

Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Research and development compensation and personnel-related expenses
$11.05M+14.6%
Globus Medical logo
GMEDReportable Segment — Research and Development Employee Related Costs
$27.34M+7.5%
Insmed logo
INSMReportable Segment — R&D compensation and benefit-related expenses
$72.14M+34.7%
Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Research And Development Personnel Related Excluding Equity Based Compensation
$18.54M+21.2%
Dolby Laboratories, Inc. logo
DLBReportable Segment — R&D
$53.84M+2.2%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept crnx:ResearchAndDevelopmentPersonnelExpenses.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's business segments — research and development personnel expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's business segments — research and development personnel expenses?
Crinetics Pharmaceuticals (CRNX) reported business segments — research and development personnel expenses of $30.65M in Q1 2026.
How has Crinetics Pharmaceuticals's business segments — research and development personnel expenses changed year-over-year?
Crinetics Pharmaceuticals's business segments — research and development personnel expenses increased by 19.6% year-over-year, from $25.63M to $30.65M.
What does business segments — research and development personnel expenses mean?
This metric represents the total compensation and benefits costs for employees directly involved in research and development activities. It serves as a proxy for the company's internal scientific capacity and human capital investment. Monitoring this helps assess the scale and growth of the organization's R&D workforce.